Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2019-02-11 Capital/Financing Update
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 4 TO FORM F-1
Capital/Financing Update Classification · 95% confidence The document is titled 'Amendment No. 4 to Form F-1' and is a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a preliminary prospectus for an initial public offering (IPO) of American Depositary Shares (ADSs) by Anchiano Therapeutics Ltd. The document includes detailed information about the offering, underwriting, risk factors, management, and financial data. Form F-1 is specifically used for registration statements by foreign private issuers for IPOs. This type of filing is related to capital raising activities and financing updates rather than annual reports, earnings releases, or other categories. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), indicating it is the filing itself, not just an announcement. Hence, the classification is CAP with high confidence.
2019-02-11 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is a registration statement for securities listing, specifically for American Depositary Shares and ordinary shares on The Nasdaq Stock Market. The document does not contain financial statements, earnings data, or management discussion, but rather is a regulatory filing for securities registration. The document length is 4007 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, this document fits best under the category of Regulatory Filings (RNS).
2019-02-08 English
Regulatory Filings 2019
Regulatory Filings
2019-02-08 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Oppenheimer & Co. Inc., acting as representative of underwriters, addressed to the SEC regarding a Registration Statement on Form F-1 for Anchiano Therapeutics Ltd. It requests acceleration of the effective date of the Registration Statement and discusses distribution of preliminary prospectuses and compliance with SEC rules. The document is short (1881 characters) and is a correspondence related to a securities offering registration, not the registration statement itself or a financial report. It is an announcement or communication related to regulatory filings rather than a full report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2019-02-07 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Anchiano Therapeutics Ltd. to the SEC requesting acceleration of the effective date for a Registration Statement on Form F-1. It references the Registration Statement filing and the Securities Act of 1933. The content is a formal communication about the timing of a registration statement becoming effective, not the registration statement itself or any financial data. The document length is short (1605 characters) and it is clearly an announcement/request related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full report or financial document.
2019-02-07 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC responding to comments on a Registration Statement on Form F-1. It discusses amendments to the Registration Statement, responses to SEC staff comments, and updates to financial and compensation disclosures. The document is not the Registration Statement itself but an amendment and response letter related to the registration process for a securities offering. This type of document is a regulatory filing related to securities registration and amendments, not a financial report, earnings release, or other specific report type. Therefore, it fits best under Regulatory Filings (RNS). The document length is about 5,227 characters, which is consistent with a detailed regulatory correspondence rather than a full report.
2019-02-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.